Nephrosclerosis: A Term in Quest of a Disease

Nephron

Volumn 129, Issue 4, 2015, Pages 276-282

  Meyrier, Alain ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Aging; Antihypertensive drugs; APOL1; Black race; FSGS; Genetics; Hypertension; Nephrosclerosis; Renal autoregulation; Renal hypoxia

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN L1;

AFRICAN; AGING; ANTIHYPERTENSIVE THERAPY; APOL1 GENE; ARTICLE; ASIAN; ATHEROSCLEROSIS; AUTOREGULATION; BLACK PERSON; BLOOD PRESSURE REGULATION; CAUCASIAN; DISEASE EXACERBATION; DYSLIPIDEMIA; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GENE; GENETIC VARIABILITY; GLOMERULUS; GLUCOSE INTOLERANCE; HEREDITY; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; MORPHOMETRY; NEPHROSCLEROSIS; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; SMOKING; COMPLICATION; NOMENCLATURE; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

HUMANS; HYPERTENSION; NEPHROSCLEROSIS; RISK FACTORS; TERMINOLOGY AS TOPIC;

EID: 84951908937     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000381195     Document Type: Article

References (55)

1. Fahr T: Über Nephrosklerose. Virchows Arch (Pathol Anat) 1919; 26: 119-178.
2. Heidland A, Gerabek W, Sebekova K: Franz Volhard and Theodor Fahr: achievements and controversies in their research in renal disease and hypertension. J Hum Hypertens 2001; 15: 5-16.
3. Shevchenko YL, Tsitlik JE: 90th Anniversary of the development by Nikolai S. Korotkoff of the auscultatory method of measuring blood pressure. Circulation 1996; 94: 116-118.
4. Goldblatt H: Hypertension and vascular disease. Circulation 1960; 21: 643-645.
5. Papper S: Nephrosclerosis; in Strauss MB, Welt LG (eds): Diseases of the Kidney. Boston, Little, Brown and Co, 1963, chapter 15, pp 501-525.
6. Heptinstall RH: Pathology of the kidney, ed 3. Little, Brown and Co, 1983, chapter 5, vol 1, pp 181-246.
7. Fogo A, Breyer JA, Smith MC, et al: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51: 244-252.
8. Kopp JB: Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens 2013; 22: 266-272.
9. Griffin KA, Kramer H, Bidani AK: Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008; 294:F685-F696.
10. Grobe JL, Rahmouni K: The adipose/circulating renin-angiotensin system cross-talk enters a new dimension. Hypertension 2012; 60: 1389-1390.
11. Kasiske BL: Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987; 31: 1153-1159.
12. Farris AB, Colvin RB: Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 2012; 21: 289-300.
13. Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 867-872.
14. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Am Soc Nephrol 2006; 17: 17-25.
15. Higgins DF, Kimura K, Bernhardt WM, et al: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007; 117: 3810-3820.
16. Neusser MA, Lindenmeyer MT, Moll AG, et al: Human nephrosclerosis triggers a hypoxia-related glomerulopathy. Am J Pathol 2010; 176: 594-607.
17. Haase VH: Hypoxia-inducible factor signaling in the development of kidney fibrosis. Fibrogenesis Tissue Repair 2012; 5(suppl 1): S16.
18. Haase VH: Oxygen regulates epithelial-tomesenchymal transition: insights into molecular mechanisms and relevance to disease. Kidney Int 2009; 76: 492-499.
19. Just A: Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am J Physiol Regul Integr Comp Physiol 2007; 292:R1-R17.
20. Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987; 252:F1003-F1010.
21. Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA: Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 2013; 22: 1-9.
22. Pelayo JC, Westcott JY: Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. J Clin Invest 1991; 88: 101-105.
23. Griffin KA, Picken M, Bidani AK: Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 1994; 4: 2023-2031.
24. Hayashi K, Epstein M, Loutzenhiser R, Forster H: Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992; 2: 1578-1586.
25. Takenaka T, Forster H, De Micheli A, Epstein M: Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ Res 1992; 71: 471-480.
26. Wang X, Ajikobi DO, Salevsky FC, Cupples WA: Impaired myogenic autoregulation in kidneys of Brown Norway rats. Am J Physiol Renal Physiol 2000; 278:F962-F969.
27. Van Dokkum RP, Sun CW, Provoost AP, et al: Altered renal hemodynamics and impaired myogenic responses in the fawn-hooded rat. Am J Physiol 1999; 276:R855-R863.
28. Kimura K, Tojo A, Hirata Y, et al: Morphometric analysis of renal arterioles in subtotally nephrectomized rats. J Lab Clin Med 1993; 122: 273-283.
29. Iversen BM, Amann K, Kvam FI, et al: Increased glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex. Am J Physiol 1998; 274:F365-F373.
30. Christensen PK, Hommel EE, Clausen P, et al: Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. Kidney Int 1999; 56: 1517-1523.
31. Griffin KA, Picken MM, Bidani AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793-800.
32. Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998; 9: 2096-2101.
33. Smeda JS, Lee RM, Forrest JB: Prenatal and postnatal hydralazine treatment does not prevent renal vessel wall thickening in SHR despite the absence of hypertension. Circ Res 1988; 63: 534-542.
34. Bridoux F, Hazzan M, Pallot JL, et al: Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992; 7: 100-104.
35. Meyrier A: Nephrosclerosis: update on a centenarian. Nephrol Dial Transplant 2014;pii: gfu366.
36. Hill GS, Heudes D, Bariéty J: Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. Kidney Int 2003; 63: 1027-1036.
37. Hill GS, Heudes D, Jacquot C, Gauthier E, Bariéty J: Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006; 69: 823-831.
38. Hill GS: Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 2008; 17: 266-270.
39. Tracy RE: Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Semin Nephrol 1996; 16: 126-133.
40. Tracy RE, Bhandaru SY, Oalmann MC, Guzman MA, Newmann WP 3rd: Blood pressure and nephrosclerosis in black and white men and women aged 25 to-54. Mod Pathol 1991; 4: 602-609.
41. Tracy RE, Malcom GT, Oalmann MC, Qureshi U, Ishii T, Velez-Duran M: Renal microvascular features of hypertension in Japan, Guatemala, and the United States. Arch Pathol Lab Med 1992; 116: 50-55.
42. Tracy RE, Guzman MA, Oalmann MC, Newman WP 3rd, Strong JP: Nephrosclerosis in three cohorts of Black and White men born 1925 to 1944, 1934 to 1953, and 1943 to 1962. Am J Hypertens 1993; 6: 185-192.
43. Kopp JB, Smith MW, Nelson GW, et al: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184.
44. Genovese G, Friedman DJ, Ross MD, et al: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
45. Madhavan SM, O'Toole JF, Konieczkowski M, et al: APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011; 22: 2119-2128.
46. Lipkowitz MS, Freedman BI, Langefeld CD, et al: Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013; 83: 114-120.
47. Chang J, Ma JZ, Zeng Q, et al: Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). Am J Physiol Renal Physiol 2013; 304:F348-F355.
48. Schlessinger SD, Tankersley MR, Curtis JJ: Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis 1994; 23: 655-660.
49. Freedman BI, Iskandar SS, Appel RG: The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995; 25: 207-221.
50. Meyrier A, Simon P: Nephroangiosclerosis and hypertension: things are not as simple as you might think. Nephrol Dial Transplant 1996; 11: 2116-2120.
51. Murea M, Freedman BI: Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens 2010; 19: 235-241.
52. Skorecki KL, Wasser WG: Hypertensionmisattributed kidney disease in African Americans. Kidney Int 2013; 83: 6-9.
53. Hsu CY: Does non-malignant hypertension cause renal insufficiency Evidence-based perspective. Curr Opin Nephrol Hypertens 2002; 11: 267-272.
54. Wright JT Jr, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
55. Parsa A, Kao WH, Xie D, et al: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196.